Kymera Therapeutics, Inc.
KYMR
주식 순위
#2179
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to... Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.
주가
$114.06
시가총액
$9.38B
변동 (1일)
5.54%
변동 (1년)
88.52%
국가
US
거래 Kymera Therapeutics, Inc. (KYMR)
카테고리
Healthcare
Kymera Therapeutics, Inc. (KYMR)의 P/B 비율
October 2026 기준 P/B 비율 TTM: 6.95
Kymera Therapeutics, Inc.의 최신 재무 보고서와 주가에 따르면 현재 P/B 비율(TTM)은 6.95입니다. 2023년 말 기준 P/B 비율은 3.76였습니다.
Kymera Therapeutics, Inc.의 P/B 비율 기록 (2018 ~ 2026)
매년 말 P/B 비율
| 연도 | P/B 비율 | 변화 |
|---|---|---|
| 2026 (TTM) | 6.95 | 92.50% |
| 2024 | 3.61 | -3.97% |
| 2023 | 3.76 | 36.99% |
| 2022 | 2.75 | -58.57% |
| 2021 | 6.63 | -31.88% |
| 2020 | 9.73 | -148.89% |
| 2019 | -19.91 | -53.72% |
| 2018 | -43.01 | 0.00% |
유사 기업 또는 경쟁사의 P/B 비율
| 회사 | P/B 비율 | P/B 비율 차이 | 국가 |
|---|---|---|---|
| 6.251 | -10.05% |
US
|
|
| 13.2547 | 90.73% |
US
|
|
| 4.208 | -39.45% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -11.04% |
NL
|
